Topical steroids for dermatitis

The most common side effect of topical corticosteroid use is skin atrophy. All topical steroids can induce atrophy, but higher potency steroids, occlusion, thinner skin, and older patient age increase the risk. The face, the backs of the hands, and intertriginous areas are particularly susceptible. Resolution often occurs after discontinuing use of these agents, but it may take months. Concurrent use of topical tretinoin (Retin-A) % may reduce the incidence of atrophy from chronic steroid applications. 30 Other side effects from topical steroids include permanent dermal atrophy, telangiectasia, and striae.

Bentonite clay!!! Aztec Indian Healing Clay! Bathe in it for 1-2 hours, facial/hand masks for 30mins, drink two cups of it daily. It is helping me so much with my tsw journey I can not stress how powerful this thing is in helping my body detox from the many years of corticosteroid usage! Please help me spread this message to all TSW sufferers, we should not have to go through the hell that this sickness inflicts on us mentally, physically, and spiritually. Dead sea salt baths mixed with a cup of bentonite clay is double the effective!! Spread the word and do more research if you do not believe me!

An Alternative Treatment

Decreased tear meniscus in dry eye.
As an alternative to steroids—or as an adjunctive therapy—topical cyclosporine can also be used to control inflammation in dry eye disease. While cyclosporine does not demonstrate the rapid anti-inflammatory effect of steroids, it carries fewer risks and is safe for long-term use.
Because of their complementary efficacy and safety profiles, many practitioners often begin dry eye treatment by prescribing both topical steroids and cyclosporine. Following the recommendation of the Asclepius Panel, the use of combination therapy is instituted with the topical corticosteroid, Lotemax (loteprednol etabonate ophthalmic suspension %, Bausch + Lomb) and Restasis (cyclosporine ophthalmic emulsion %, Allergan). 24 The Asclepius Panel recommends practitioners begin early treatment with an anti-inflammatory agent (such as Lotemax) four times a day to improve symptoms and to prevent disease progression. After two weeks, the frequency of the corticosteroid is reduced to twice daily and supplemented with Restasis twice a day. Treatment with loteprednol was stopped after day 60, while cyclosporine treatment is continued.

-Solution, ointment, gel, foam, cream formulations: Apply a thin layer to affected areas twice a day and rub in gently and completely. Not recommended for use in children under 12 years of age.
-Shampoo, spray, and lotion formulations: Not recommended for use in children under 18 years of age.

Maximum dose: The total dosage should not exceed 50 g (50 mL or fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis; recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions which do not respond satisfactorily to less active steroids.

Topical steroids for dermatitis

topical steroids for dermatitis

-Solution, ointment, gel, foam, cream formulations: Apply a thin layer to affected areas twice a day and rub in gently and completely. Not recommended for use in children under 12 years of age.
-Shampoo, spray, and lotion formulations: Not recommended for use in children under 18 years of age.

Maximum dose: The total dosage should not exceed 50 g (50 mL or fl. oz.) per week.

Duration of therapy: Treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that
have not improved after the initial 2 weeks of treatment.

Comments: Unless directed by a healthcare professional, this drug should not be used with occlusive dressings.

Uses:
-Corticosteroid-responsive inflammatory and pruritic dermatoses; psoriasis; recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions which do not respond satisfactorily to less active steroids.

Media:

topical steroids for dermatitistopical steroids for dermatitistopical steroids for dermatitistopical steroids for dermatitistopical steroids for dermatitis

http://buy-steroids.org